NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Highlights Study Showing MammaPrint/BluePrint Tests Predict Response to Current Breast Cancer Chemotherapy and Targeted Therapy Regimens
Researchers Present Data at Breast Cancer Symposiumย Showing MammaPrint/BluePrint Can Identify Womenย Who Benefit from Chemotherapy and Targetedย Dual Anti-HER2 Drug Treatment Before Surgery IRVINE, CA and AMSTERDAM, THE NETHERLANDS โ Agendiaโs MammaPrintยฎ and BluePrintยฎ tests provide new Read More
Agendia Board of Directors Appoints Mark R. Straley as New CEO
IRVINE, CA and AMSTERDAM โ Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announced the appointment of veteran diagnostics industry leader Mark R. Straley as Chief Executive Officer. ย He succeeds Read More
NCCN Breast Cancer Guidelines Acknowledge MammaPrintโs Ability to Predict Prognosis
Respected Panel Cites RASTER, the Only Published Prospective Outcome Data of Its Kind, Which Demonstrates MammaPrintโs Ability to Identify Those Patients Who May Safely Forego Chemotherapy IRVINE, CA and AMSTERDAM, THE NETHERLANDS โ Agendia, a Read More